Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Clarivate Plc Ordinary Shares (CLVT)
Company Research
Source: PR Newswire
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient careLONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform care within five years. Drugs to Watch has consistently identified therapies that redefine patient care, with over 110 featured to date, making it a central reference for tracking innovation in the pharmaceutical sector.Drawing on Clarivate integrated data assets and AI-powered intelligence, the report identifies emerging therapies
Show less
Read more
Impact Snapshot
Event Time:
CLVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLVT alerts
High impacting Clarivate Plc Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CLVT
News
- Clarivate (NYSE:CLVT) was downgraded by analysts at The Goldman Sachs Group, Inc. to a "neutral" rating.MarketBeat
- Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report [Yahoo! Finance]Yahoo! Finance
- Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch ReportPR Newswire
- Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch ReportPR Newswire
CLVT
Earnings
- 10/29/25 - Beat
CLVT
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- CLVT's page on the SEC website